Page last updated: 2024-08-23

raloxifene hydrochloride and Hyperparathyroidism

raloxifene hydrochloride has been researched along with Hyperparathyroidism in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Marcus, R	1
Lee, KH; McMahon, DJ; Rubin, MR; Silverberg, SJ	1
Bogado, CE; Zanchetta, JR	1

Reviews

1 review(s) available for raloxifene hydrochloride and Hyperparathyroidism

Article	Year
The role of estrogens and related compounds in the management of primary hyperparathyroidism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17 Suppl 2 Topics: Bone Density; Calcium; Estrogens; Humans; Hyperparathyroidism; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002

Trials

2 trial(s) available for raloxifene hydrochloride and Hyperparathyroidism

Article	Year
Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:3 Topics: Biomarkers; Bone Remodeling; Calcium; Double-Blind Method; Female; Humans; Hyperparathyroidism; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2003
Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:1 Topics: Aged; Alkaline Phosphatase; Bone Density; Calcium; Creatinine; Female; Femur Neck; Humans; Hyperparathyroidism; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors	2001

Article

Year

Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.

The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:3

Topics: Biomarkers; Bone Remodeling; Calcium; Double-Blind Method; Female; Humans; Hyperparathyroidism; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators

2003

Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:1

Topics: Aged; Alkaline Phosphatase; Bone Density; Calcium; Creatinine; Female; Femur Neck; Humans; Hyperparathyroidism; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors

2001